Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Optimal Toxicity Management With BTK Inhibitors in CLL

August 16th 2021

Brad S. Kahl, MD, shares practical advice on the management of BTK inhibitor–related toxicity in patients with chronic lymphocytic leukemia.

Head-to-Head Analysis of Acalabrutinib Vs Ibrutinib in Previously Treated CLL

August 16th 2021

Considerations for the head-to-head data out of ASCO 2021 comparing acalabrutinib and ibrutinib in previously treated chronic lymphocytic leukemia.

4-Year Follow-up Data From ELEVATE-TN: Frontline Acalabrutinib in CLL

August 16th 2021

Insight on the 4-year follow-up data from ELEVATE-TN and the frontline use of acalabrutinib, with or without anti-CD20 therapy, in patients with CLL.

Frontline BTK Inhibition in CLL: 7-Year Follow-up Data From RESONATE-2

August 16th 2021

Brad S. Kahl, MD, reflects on the 7-year follow-up data from the RESONATE-2 trial, which tested ibrutinib as frontline therapy in patients with CLL.

Revolutionizing the Management of Chronic Lymphocytic Leukemia

August 16th 2021

A comprehensive analysis of the CLL treatment landscape, including available agents, risk stratification, and triggers to initiate therapy.

Optimizing the Frontline Management of High-Risk CLL

August 16th 2021

After determining the parameters of high-risk CLL, key opinion leaders clarify optimal frontline management strategies.

Dr. Danilov on the Efficacy of the Combination Zandelisib and Zanubrutinib in R/R B-Cell Malignancies

August 13th 2021

Alexey V. Danilov, MD, PhD, discusses the efficacy seen in the ongoing phase 1b study examining the combination of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.

BTK Inhibitors Represent the Preferred Frontline Regimen in CLL

August 13th 2021

The majority of patients with newly diagnosed chronic lymphocytic leukemia have better outcomes with BTK inhibitors compared with standard chemoimmunotherapy, making them the logical choice for frontline therapy.

Acalabrutinib Induces Durable Disease Control in Frontline CLL at 4 Years

August 11th 2021

Acalabrutinib, alone or in combination with obinutuzumab, demonstrated superior efficacy and an acceptable safety profile in patients with treatment-naïve chronic lymphocytic leukemia.

Dr. Thompson on the Evolving Role of MRD Testing in CLL

August 11th 2021

Meghan Thompson, MD, discusses the evolving role of minimal residual disease testing in chronic lymphocytic leukemia.

Dr. Roeker on the Rationale for BTK/Venetoclax Combos in CLL

August 10th 2021

Lindsey Roeker, MD, discusses the rationale for combining venetoclax with BTK inhibitors for use in patients with chronic lymphocytic leukemia.

Fixed-Duration Ibrutinib/Venetoclax Provides Deep, Durable Responses in Frontline CLL/SLL

August 10th 2021

A fixed duration of ibrutinib plus venetoclax has demonstrated durable efficacy when used in the frontline treatment of patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (SLL).

BCL2 Inhibitors in Previously Untreated CLL

August 10th 2021

Experts discuss the optimal approach for choosing between a Bruton tyrosine kinase (BTK) inhibitor–based therapy vs a BCL2 inhibitor–based regimen for frontline chronic lymphocytic leukemia (CLL) therapy.

ALPINE Study: Zanubrutinib vs Ibrutinib in R/R CLL

August 10th 2021

An overview of the h ALPINE trial of zanubrutinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Key Clinical Data for Frontline Targeted Therapy in CLL

August 9th 2021

Shared insight on clinical trial data for frontline targeted agents—specifically ibrutinib, acalabrutinib, and venetoclax—in chronic lymphocytic leukemia.

Global Approaches to the Frontline Management of CLL

August 9th 2021

Considering a patient’s age, as well as their deletion 17p and IgHV status, experts from around the world share their approach to the frontline management of CLL.

Investigators Look to Enhance Response With Novel Triplet in CLL

August 5th 2021

Investigators of the phase 3 ULTRA-V trial are look-ing to leverage the synergistic capabilities of venetoclax for patients with chronic lymphocytic leukemia with the addition of the U2 regimen of ublituximab in combination with umbralisib.

Dr. Thompson on Future Research Directions in CLL

August 5th 2021

Meghan Thompson, MD, discusses future research directions in chronic lymphocytic leukemia.

Mitigating Toxicities Associated With BTK Inhibitors

August 3rd 2021

A continuing discussion about the implications of toxicities with BTK inhibitors.

Safety and Efficacy of BTK Inhibitors in CLL

August 3rd 2021

A discussion about managing toxicities associated with Bruton tyrosine kinase (BTK) inhibitors for chronic lymphocytic leukemia (CLL).